Literature DB >> 16556170

Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression.

P Malfertheiner1, R Fass, E M M Quigley, I M Modlin, J R Malagelada, S F Moss, G Holtmann, K-L Goh, P Katelaris, V Stanghellini, N J Talley, G N Tytgat, N A Wright.   

Abstract

To commemorate Edkins' discovery of gastrin in 1905, we review a century of progress in the physiology and pathobiology of gastrin and acid secretion especially as it pertains to clinical aspects of gastro-oesophageal reflux disease. Although initially ignored, Edkins' observations eventually led to the enthusiastic investigation of gastrin and acid regulation in peptic ulcer disease, culminating in important therapeutic advances in the management of acid peptic disease. Following the improved understanding of gastric secretory physiology, and the development of acid suppressants with increasing efficacy, the use of surgical intervention for peptic ulcer disease was almost eliminated. Surgery became obsolete with the discovery of Helicobacter pylori. Three other advances are also influencing modern practice: the gastrotoxicity of aspirin and non-steroidal anti-inflammatory drugs is now increasingly appreciated, the role of endoscopy in the diagnosis and therapy of upper gastrointestinal bleeding, and the use of intravenous acid-suppressive agents. The major issue for the future resides within the epidemic of gastro-oesophageal reflux disease. How to diagnose, categorize and treat this condition and how to identify and prevent neoplasia, are the challenges of the new century.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556170     DOI: 10.1111/j.1365-2036.2006.02817.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Selective-serotonin reuptake inhibitors for the treatment of hypersensitive esophagus.

Authors:  Nikos Viazis; George Karamanolis; Eleni Vienna; Dimitrios G Karamanolis
Journal:  Therap Adv Gastroenterol       Date:  2011-09       Impact factor: 4.409

2.  Acid peptic diseases: pharmacological approach to treatment.

Authors:  Alex Mejia; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2009-05       Impact factor: 5.045

3.  Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor.

Authors:  Claudia Cristina de Sá; Humberto Setsuo Kishi; Ana Luiza Silva-Werneck; Joaquim Prado Pinto de Moraes-Filho; Jaime Natan Eisig; Ricardo Correa Barbuti; Claudio Lyioti Hashimoto; Tomas Navarro-Rodriguez
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Study of respiratory disorders in endoscopically negative and positive gastroesophageal reflux disease.

Authors:  Maha M Maher; Amr A Darwish
Journal:  Saudi J Gastroenterol       Date:  2010 Apr-Jun       Impact factor: 2.485

5.  Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients.

Authors:  Su Yeong Kim; Na Mi Lee; Sin Weon Yun; Soo Ahn Chae; In Seok Lim; Eung Sang Choi; Dae Yong Yi
Journal:  Korean J Pediatr       Date:  2019-07-03

6.  Impact of PPIs on patient focused symptomatology in GERD.

Authors:  Abr Thomson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

7.  Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors.

Authors:  Daisuke Asaoka; Akihito Nagahara; Mariko Hojo; Kenshi Matsumoto; Hiroya Ueyama; Kohei Matsumoto; Kentaro Izumi; Tsutomu Takeda; Hiroyuki Komori; Yoichi Akazawa; Yuji Shimada; Taro Osada; Sumio Watanabe
Journal:  Biomed Rep       Date:  2016-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.